Peptides are reshaping how researchers attack tumors, offering a middle ground between traditional small-molecule drugs and large antibody therapies. These short chains of amino acids can home in on cancer cells, ferry toxic payloads past healthy tissue, punch holes in tumor membranes, deliver radiation to specific receptors, and even train the immune system to recognize malignant cells. One peptide-based radionuclide therapy has already earned FDA approval for neuroendocrine tumors, and dozens of other peptide platforms are in clinical trials for cancers ranging from prostate to breast to pancreatic. The field is broad and fast-moving, so understanding the distinct strategies in play helps make sense of where cancer therapy is headed.
Finding the Right Peptide for the Job
Before a peptide can treat cancer, researchers have to find one that binds tightly to something on or around tumor cells without grabbing onto healthy tissue. One of the most productive tools for this search is phage display, a technique that lets scientists sift through billions of candidate peptides at once. Bacteriophages, the viruses that infect bacteria, are engineered so that each one displays a different short peptide on its surface. Those phages are then washed over a target, and the ones that stick are collected, amplified, and washed over the target again. After several rounds of this enrichment process, the surviving peptides tend to bind the target with high affinity and selectivity.1PubMed Central. Phage display screening of therapeutic peptide for cancer targeting and therapy This approach has produced peptide leads that recognize receptors overexpressed on specific tumor types, markers on tumor blood vessels, and proteins unique to the tumor microenvironment.2Current drug discovery technologies. Is phage display technology on target for developing peptide-based cancer drugs?
Peptide-Drug Conjugates
One of the most active areas of development treats the peptide itself as a delivery vehicle rather than a weapon. In a peptide-drug conjugate, a short targeting peptide (typically five to thirty amino acid residues) is connected through a chemical linker to a potent cytotoxic drug. The peptide steers the whole assembly to the tumor, and the linker is designed to stay intact in the bloodstream but release the drug once it reaches the tumor microenvironment.3PubMed Central. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic The result is that higher concentrations of the toxic payload accumulate at the tumor while the rest of the body sees less of it.
Compared to antibody-drug conjugates, which use full-sized antibodies as carriers, peptide-drug conjugates are smaller and penetrate solid tumors more easily. They are also cheaper and simpler to manufacture. Because peptides can be synthesized chemically rather than grown in living cells, scaling production is more straightforward.4PubMed Central. Peptide Drug Conjugates and Their Role in Cancer Therapy Beyond simple delivery, recent work suggests that peptide-drug conjugates can trigger a form of cancer cell death that activates the immune system, potentially turning a local treatment into one that reshapes the immune environment of the tumor.5PubMed. Peptide-drug conjugates in tumor therapy: Current advances and future perspectives
Getting Through the Cell Membrane
Many promising cancer drugs fail because they cannot cross the cell membrane to reach their targets inside the cell. Cell-penetrating peptides solve this problem. These are short sequences, generally under thirty amino acids, that can pass through cell membranes and carry cargo with them.6PubMed Central. Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer The cargo can be a drug, a strand of genetic material, or an imaging agent. Cell-penetrating peptides overcome one of the fundamental barriers in drug delivery, and they have been tested in both preclinical models and early clinical trials.7PubMed Central. Cancer-Targeting Applications of Cell-Penetrating Peptides
A key challenge with cell-penetrating peptides is selectivity. Because their membrane-crossing ability is somewhat indiscriminate, researchers often pair them with a targeting element, such as a homing peptide that recognizes a tumor-specific receptor, or a chemical switch that activates only in the acidic conditions found inside tumors. Without that added specificity, the peptide ferries its cargo into healthy cells too.
Targeting Tumor Blood Vessels
Tumors need blood vessels to grow, and the vessels that feed tumors are structurally different from normal blood vessels. They express certain integrins on their surface at unusually high levels. RGD peptides, named for the arginine-glycine-aspartate sequence they contain, bind to those integrins and can be used to target both the tumor cells themselves and the blood vessel cells that support the tumor.8PubMed Central. RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions
This dual targeting is useful because destroying the tumor’s blood supply starves it of oxygen and nutrients. In one approach, RGD-modified nanoparticles carrying genetic material that silences a key blood-vessel growth factor were shown to enhance uptake in tumor-associated blood vessel cells compared to non-targeted particles.9PubMed. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles RGD peptides have become one of the most widely used tumor-homing motifs in the field, appearing in drug conjugates, imaging agents, and nanoparticle coatings alike.
Peptides That Kill by Destroying Membranes
Not all anticancer peptides work by delivering a separate drug. Some kill cancer cells directly by physically disrupting their membranes. These membrane-disrupting peptides are typically short, positively charged, and adopt a shape that lets them insert into and tear apart the lipid bilayer of a cell. The mechanism is fundamentally different from conventional chemotherapy, which usually targets a specific protein or DNA process inside the cell.10PubMed Central. Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era
Cancer cell membranes tend to carry a higher negative charge on their surface than normal cells, which gives positively charged peptides a degree of selectivity. Peptides with the right structural features can cause near-instant cell death through membrane lysis.11PubMed. Amphipathicity Determines Different Cytotoxic Mechanisms of Lysine- or Arginine-Rich Cationic Hydrophobic Peptides in Cancer Cells Recent work on peptides derived from natural sources, including snake venom components, has confirmed this membrane-disruption pathway in human breast cancer cells, with evidence showing significant membrane permeabilization without the hallmarks of the slower apoptotic cell-death pathway.12PubMed. Crotalicidin and NA-CATH-ATRA-1-ATRA-1 peptide-induced membrane disruption in human breast cancer cells Because this mechanism does not rely on a single molecular target, it is harder for cancer cells to develop resistance to it, which is a major advantage in an era when drug resistance derails many treatments.
One refinement of this approach uses “propeptides” that remain inactive in the bloodstream. The peptide’s membrane-disrupting charge is masked by an acidic domain. When cancer-associated enzymes in the tumor environment cleave that domain away, the active peptide is released and deposits on nearby cancer cell surfaces.13Molecular Cancer Therapeutics. Protease-Activated Pore-Forming Peptides for the Treatment and Imaging of Prostate Cancer This activation-on-site strategy could reduce the amount of peptide needed and limit off-target effects.
Peptide Receptor Radionuclide Therapy
The clearest clinical success story for peptides in oncology is peptide receptor radionuclide therapy, or PRRT. In this approach, a peptide that binds to somatostatin receptors, which are overexpressed on certain neuroendocrine tumors, is tagged with a radioactive atom. When injected, the peptide-radioisotope compound seeks out the tumor cells, binds to their receptors, and delivers a focused dose of radiation from the inside.
Lutetium-177-DOTATATE (sold as Lutathera) became the first approved agent in this class after the NETTER-1 phase III trial showed it prolonged progression-free survival and improved quality of life in patients with midgut neuroendocrine tumors that no longer responded to standard somatostatin analogues. It received European approval in 2017 and FDA approval in 2018.14PubMed Central. Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions The more recent NETTER-2 trial has extended these findings, supporting the use of PRRT as a first-line treatment in higher-grade neuroendocrine tumors, not just as a later-line option.15PubMed. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
Beyond the approved agent, the field is branching into new territory. Researchers are testing somatostatin receptor antagonists instead of agonists, which may bind to more receptor sites on each tumor cell and deliver a larger radiation dose. Alpha-emitting radioisotopes are also under investigation because they deposit their energy over a shorter distance, potentially sparing more of the surrounding healthy tissue while hitting resistant disease harder.14PubMed Central. Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions
Peptide-Based Checkpoint Inhibitors
Immunotherapy with checkpoint-blocking antibodies has transformed cancer treatment over the past decade, but those antibodies are large, expensive, and sometimes struggle to penetrate solid tumors deeply. Peptide-based inhibitors that block the same immune checkpoints are a promising alternative. The PD-1/PD-L1 axis, one of the most important immune checkpoints, has been a primary target. Several research groups have designed peptides that bind to PD-L1 and prevent it from engaging PD-1 on T cells, effectively releasing the immune system’s brake on attacking the tumor.
One peptide mimic of PD-1, called MOPD-1, showed nanomolar affinity for PD-L1, remained stable in human serum, and inhibited tumor growth in animal models.16PubMed. Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy Another peptide, CLP002, showed better tumor penetration than antibodies in a three-dimensional tumor model, restored T cell activity when cancer cells were present, and slowed tumor growth in mice.17Journal for ImmunoTherapy of Cancer. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy These are still preclinical results, but peptide checkpoint inhibitors could eventually offer cheaper and more tissue-penetrant alternatives to current antibody-based immunotherapies.
Stapled Peptides and Disrupting Cancer’s Internal Signals
Inside cancer cells, proteins often interact with each other in ways that promote tumor survival. One of the most studied of these interactions involves the protein MDM2, which binds to and inactivates p53, a tumor suppressor that normally forces damaged cells to self-destruct. In many cancers, MDM2 is overproduced, keeping p53 suppressed and letting the cancer grow unchecked.
Designing a drug to block a protein-protein interaction is notoriously difficult because the contact surface between two proteins is large and flat, unlike the small pockets that conventional drugs typically fit into. Stapled peptides offer a workaround. These are short peptide sequences with a chemical brace connecting two of their amino acid side chains, locking the peptide into a rigid, helical shape that mimics the natural binding surface of one protein partner. This staple also makes the peptide more resistant to breakdown by enzymes and better able to enter cells.18PubMed Central. Stapled peptides as scaffolds for developing radiotracers for intracellular targets Stapled peptides designed to block the p53-MDM2 interaction are among the most advanced examples, with active research into how they bind, how water molecules at the binding interface affect their potency, and how to improve their drug-like properties.19PubMed. Microscopic Insights into the Solvation of Stapled Peptides-A Case Study of p53-MDM2
Peptides in Cancer Imaging and Diagnostics
Peptides are not only therapeutic agents; they also serve as the backbone for diagnostic imaging tools. When a tumor-targeting peptide is labeled with a radioactive tracer, it can light up tumors on a PET or SPECT scan. Peptides are well suited for this because they clear from the bloodstream quickly and bind their targets with high selectivity, which together produce images with strong contrast between tumor and background tissue.20PubMed Central. Peptide-based imaging agents for cancer detection
Several radiolabeled peptides have already received FDA approval for diagnostic use, and many more are in late-stage clinical trials.21PubMed Central. Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine Innovative platforms now combine imaging and therapy in a single system, sometimes called theranostics. For example, the same peptide scaffold can be labeled with a diagnostic isotope for imaging and then swapped to a therapeutic isotope for treatment, allowing clinicians to see which patients’ tumors take up the peptide before committing them to therapy.22PubMed Central. Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment
Why Peptides Are Hard to Turn Into Drugs
For all their promise, peptides have real weaknesses as drugs. They are readily chewed up by enzymes in the blood and gut, which gives them short half-lives and generally poor oral bioavailability. Most peptide drugs need to be injected. They are also small enough to be filtered rapidly through the kidneys, which limits how long they circulate and how much reaches the tumor.23PubMed Central. HPMA Copolymers: A Versatile Platform for Targeted Peptide Drug Delivery
Kidney retention creates a second problem beyond short circulation times. When radiolabeled peptides used in PRRT are reabsorbed in the kidney’s proximal tubules, they deposit radiation there, and the resulting kidney toxicity can become dose-limiting, preventing clinicians from giving enough of the drug to be maximally effective against the tumor.24Journal of Nuclear Medicine. Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
Researchers have developed a toolkit of chemical modifications to address these limitations. Strategies include capping the ends of the peptide chain, swapping in non-natural amino acid forms that enzymes do not recognize, attaching polyethylene glycol chains to increase size and circulation time, and cyclizing the peptide to make it more rigid and enzyme-resistant.25PubMed Central. Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals Cyclization in particular has shown benefits for both metabolic stability and cellular uptake.26PubMed. Cyclization of a cell-penetrating peptide via click-chemistry increases proteolytic resistance and improves drug delivery Polymer conjugation, such as attaching peptides to large water-soluble polymer backbones, can circumvent renal clearance and prolong circulation while still allowing the drug to accumulate at the tumor and release under specific conditions.23PubMed Central. HPMA Copolymers: A Versatile Platform for Targeted Peptide Drug Delivery
Self-assembling peptide hydrogels represent yet another delivery approach. Certain peptides can spontaneously organize into structures like micelles, gels, or vesicles that can encapsulate drugs and respond to internal signals such as pH changes or enzyme activity to release their contents at a tumor site.27PubMed Central. Multifunctional Self-Assembled Peptide Hydrogels for Biomedical Applications
Combining Peptides With Other Treatments
Using peptides alongside conventional chemotherapy may address one of oncology’s most frustrating problems: multidrug resistance. Cancer cells that have evolved to pump drugs back out of the cell or otherwise evade chemotherapy are often still vulnerable to membrane-disrupting peptides, because a physical attack on the membrane does not rely on any of the internal mechanisms the cancer cell has learned to block. In one demonstration, a membrane-active peptide polymer combined with the chemotherapy drug doxorubicin was far more effective against drug-resistant cancer cells than doxorubicin alone, both in the lab and in animal models. The peptide increased membrane permeability, making it easier for the chemotherapy drug to get in and stay in.28PubMed. Reversing Anticancer Drug Resistance by Synergistic Combination of Chemotherapeutics and Membranolytic Antitumor β-Peptide Polymer This type of synergy, where the peptide component makes the conventional drug work better, could become especially valuable in late-stage cancers where resistance has already developed.
PRRT is also being explored in combination with chemotherapy, DNA-repair inhibitors, and immunotherapy, aiming to enhance the tumor-killing effect of the radiolabeled peptide or to convert a local radiation response into a broader immune response.14PubMed Central. Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions
Artificial Intelligence in Peptide Design
Designing anticancer peptides used to mean synthesizing and testing thousands of candidates one by one. Machine learning and deep learning tools have changed that calculus. Algorithms trained on databases of known anticancer peptides can now predict which sequences are likely to kill cancer cells, rank candidates by expected potency and selectivity, and flag peptides that are likely to be toxic or unstable before anyone has to make them in a lab.29PubMed Central. Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics The growing number of prediction tools built on machine learning reflects how quickly this approach has been adopted.30PubMed. Evolution of Machine Learning Algorithms in the Prediction and Design of Anticancer Peptides
AI-driven strategies are also being used for de novo peptide design, generating entirely new sequences rather than just filtering known ones. In a recent computational study, AI methods were used to design peptide inhibitors of a specific cancer-promoting protein called WWP1, identifying a short six-amino-acid peptide with strong predicted binding affinity.31bioRxiv. AI-Driven Computational Design of Peptide-Based WWP1 Inhibitors as Promising Therapeutic Agents Against Breast Cancer, Including Triple-Negative Subtype These computationally designed peptides still need experimental validation, but the approach dramatically speeds up the discovery process.
Neoantigen Vaccines and Personalized Peptide Immunotherapy
Perhaps the most personalized application of peptides in oncology is the neoantigen vaccine. Every tumor accumulates mutations as it grows, and some of those mutations produce altered protein fragments, called neoantigens, that appear on the tumor cell surface but nowhere else in the body. A neoantigen vaccine is a cocktail of synthetic peptides matching a given patient’s unique neoantigens, injected to train that patient’s immune system to recognize and destroy their specific tumor. These vaccines aim to produce strong and lasting immune responses that can clear existing tumors and guard against recurrence.32PubMed Central. Neoantigen cancer vaccines: a new star on the horizon
Manufacturing a unique vaccine for each patient is logistically demanding, requiring tumor sequencing, computational prediction of which neoantigens the immune system is most likely to respond to, and rapid peptide synthesis. But several neoantigen vaccine trials, particularly in melanoma and pancreatic cancer, have produced encouraging early results, and the approach is being combined with checkpoint immunotherapy to amplify the immune response.
Oral Delivery and Next-Generation Formulations
Most peptide-based cancer treatments are given by injection, which creates challenges for patient compliance and long-term use. Oral delivery of peptides has historically been considered impractical because stomach acid and digestive enzymes destroy them before they can be absorbed. However, new formulation strategies are chipping away at this barrier. Intestinal permeation enhancers, compounds that temporarily open the gut lining to let peptides pass through, have shown real progress. One such enhancer, salcaprozate sodium (SNAC), is already a key ingredient in the first FDA-approved oral semaglutide formulation for diabetes, demonstrating that oral peptide delivery is achievable in practice. Other enhancers, including sodium caprate, are being tested in clinical trials for oral insulin and could eventually extend to cancer peptides as well. Polymer-based and nanotechnology-assisted delivery systems are further broadening the options for getting peptides through the gastrointestinal tract intact.